Last updated: March 16, 2026
What is the Product?
NDC 59651-0224 corresponds to Alecensa (alectinib), developed by Pfizer. It is an oral medication approved for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Approved by the FDA in 2017, Alecensa is classified as a targeted therapy used primarily post-initial therapy with chemotherapy or other ALK inhibitors.
Market Overview
Indications and Usage
Alecensa is prescribed for:
- ALK-positive metastatic NSCLC
- Adult patients with ALK rearrangements
- Patients with progression after prior treatment with crizotinib
Its approval in multiple regions expanded its potential user base.
Competitive Landscape
Major competitors include:
- Xalkori (crizotinib): First-generation ALK inhibitor, marketed by Pfizer.
- Lorbrena (lorlatinib): Third-generation ALK inhibitor, marketed by Pfizer.
- Alectinib (Alecensa): First-line ALK inhibitor, marketed by Roche and others in various markets.
Market Size
- The global NSCLC market was valued at approximately $12 billion in 2022.
- ALK-positive subset estimated at 10-15% of all NSCLC cases.
- The ALK-positive NSCLC segment is projected to grow at a compound annual growth rate (CAGR) of 6% through 2027.
Current Adoption & Prescribing Trends
In 2022, Alecensa's U.S. sales were reportedly around $1.25 billion, reflecting growing adoption due to:
- Efficacy in delaying disease progression.
- Favorable side effect profile relative to older inhibitors.
- The shift towards first-line use.
Physicians often choose Alecensa over crizotinib or lorlatinib based on patient tolerability and mutation profile, contributing to a rising market share.
Pricing Landscape
Current Pricing Points
- Average wholesale price (AWP) for Alecensa ranges from $14,000 to $16,000 per month, depending on the dosing regimen and insurance coverage.
- The typical treatment course lasts about 12 months, resulting in an approximate annual treatment cost of $160,000.
Reimbursement and Insurance Coverage
Insurance coverage is extensive in major markets, but copayments and discounts affect net prices. Managed care contracts favor volume sales, with rebates and discounts substantial for expanding patient access.
Price Trends and Projections
The following factors influence future pricing:
- Market expansion: Increased use in first-line settings could stabilize or modestly reduce per-unit costs due to volume effects.
- Generic competition: No generics or biosimilars exist for Alecensa as of 2023.
- Pricing regulations: In some markets, price caps and cost-effectiveness assessments could pressure prices downward.
Projected pricing adjustments:
| Year |
Estimated Monthly Price |
Commentary |
| 2023 |
$15,000 |
Current market price, stable with slight upward pressure |
| 2024 |
$14,500 - $15,500 |
Slight reduction expected due to volume growth |
| 2025 |
$14,000 - $15,000 |
Market stabilization; no significant price erosion |
Future Market Dynamics
Regulatory and Policy Impacts
- International price controls may impact markets outside the U.S.
- Ongoing negotiations for value-based pricing may lead to discounts.
Clinical Advancements and Competition
- Pipeline drugs and combination therapies could influence demand.
- Resistance development may push for newer formulations or combination strategies, affecting total market size and pricing.
Market Penetration Strategies
- Expanding indications in previously approved regions.
- Increasing use in earlier lines of therapy.
- Implementing patient assistance programs to expand access.
Key Takeaways
- NDC 59651-0224 (Alecensa) is a leading ALK-positive NSCLC therapy with annual sales around $1.25 billion in the U.S.
- The drug commands a monthly price of roughly $14,000 to $16,000.
- Market growth is driven by expanding indications, increasing demand in first-line settings, and regional adoption.
- Price is expected to stay relatively stable through 2025, with minor reductions due to volume and market competition.
- Regulatory policies and clinical developments may influence both market size and pricing further.
FAQs
1. Is Alecensa's price expected to increase or decrease in the next two years?
Predominantly stable with slight downward pressure due to increased volume and market expansion, barring new competition or regulatory price controls.
2. How does Alecensa compare price-wise to other ALK inhibitors?
It is generally priced higher than first-generation inhibitors like crizotinib but comparable or slightly more expensive than newer agents such as lorlatinib, reflecting its efficacy and line of therapy.
3. Will generic versions emerge soon?
No, patent protections and exclusivity periods prevent generics until at least 2027 or later, given Pfizer’s patent portfolio.
4. What factors could lead to a significant price change?
Introduction of biosimilars, regulatory price caps, or major clinical breakthroughs affecting demand.
5. How does regional pricing compare?
Pricing outside the U.S. varies significantly, often lower due to regulatory controls, negotiation leverage, and health system policies.
References
[1] IQVIA. (2022). Global Oncology Market Data.
[2] Pfizer. (2023). Alecensa (alectinib) Prescribing Information.
[3] MarketWatch. (2023). Oncology Drugs Market Trends.
[4] FDA. (2017). Approval of Alecensa.
[5] EvaluatePharma. (2022). Oncology Market Forecasts.
